- The US budget negotiations are making progress but significant differences remain, though a deal does not seem impossible. The Fed will continue bond purchases as long as unemployment is above 6.5%.
- European industrial production fell while new car registrations dropped 10.3%. Recovery will be difficult as manufacturing PMIs stabilized and services PMIs rose slightly.
- In Switzerland, Zurich Assurances estimated Hurricane Sandy losses at $758 million, within expectations. UBS could pay $1.6 billion to settle Libor rigging charges. Holcim will write down assets by $410 million due to European restructuring.
- The US budget negotiations are making progress but significant differences remain, though a deal does not seem impossible. The Fed will continue bond purchases as long as unemployment is above 6.5%.
- European industrial production fell while new car registrations dropped 10.3%. Recovery will be difficult as manufacturing PMIs stabilized and services PMIs rose slightly.
- In Switzerland, Zurich Assurances estimated Hurricane Sandy losses at $758 million, within expectations. UBS could pay $1.6 billion to settle Libor rigging charges. Holcim will write down assets by $410 million due to European restructuring.
Marché suisse
A suivre cette semaine: commerce extérieur octobre (AFD), expor- tations horlogères octobre (FH), fortune des ménages privés 2011 (BNS). Pour les sociétés, résultats T3 de Airesis et SHL et résultats S1 de Carlo Gavazzi.
ZURICH (PLUS) a publié la semaine dernière des résultats T3 infé- rieurs aux attentes, mais robustes malgré tout. La solvabilité progresse et permet d’envisager un dividende stable pour 2012, confortable. ROCHE (PLUS) a publié des résultats intermédiaires encourageants pour Avastin dans le glioblastome (cancer du cerveau). Les données complètes sont attendues en 2013. Novartis (NR) : les experts de l’EMA (Agence européenne du médicament) recommandent l’appro- bation de Bexsero (vaccin contre les infections à méningocoques B) en Europe. Le lancement de Bexsero est important pour la pérennité et la rentabilité de la division vaccin de Novartis.
1) The US economy added more jobs than expected in October and manufacturing activity increased, while the eurozone continues to struggle with weak manufacturing.
2) Markets showed little reaction to the positive US economic data and ended the month flat as investors await the outcome of the US presidential election.
3) The report provides recommendations on several stocks to watch that are reporting earnings or announcements, including Gemalto, Intercontinental Hotels, L'Oreal, and Sodexo.
Marché suisse
A suivre cette semaine: commerce extérieur octobre (AFD), expor- tations horlogères octobre (FH), fortune des ménages privés 2011 (BNS). Pour les sociétés, résultats T3 de Airesis et SHL et résultats S1 de Carlo Gavazzi.
ZURICH (PLUS) a publié la semaine dernière des résultats T3 infé- rieurs aux attentes, mais robustes malgré tout. La solvabilité progresse et permet d’envisager un dividende stable pour 2012, confortable. ROCHE (PLUS) a publié des résultats intermédiaires encourageants pour Avastin dans le glioblastome (cancer du cerveau). Les données complètes sont attendues en 2013. Novartis (NR) : les experts de l’EMA (Agence européenne du médicament) recommandent l’appro- bation de Bexsero (vaccin contre les infections à méningocoques B) en Europe. Le lancement de Bexsero est important pour la pérennité et la rentabilité de la division vaccin de Novartis.
1) The US economy added more jobs than expected in October and manufacturing activity increased, while the eurozone continues to struggle with weak manufacturing.
2) Markets showed little reaction to the positive US economic data and ended the month flat as investors await the outcome of the US presidential election.
3) The report provides recommendations on several stocks to watch that are reporting earnings or announcements, including Gemalto, Intercontinental Hotels, L'Oreal, and Sodexo.